SyntheX is using the power of genetics and synthetic biology to build the next generation of drug discovery engines.
We create cell-based platforms to produce and functionally select molecules to target conventionally 'undruggable' proteins.
OUR TECHNOLOGY
Using genetically engineered circuits, our platform technologies rely on functional intracellular drug selection as opposed to in vitro screening. This allows us to discover compounds with novel modes of action that can modulate protein interactions in either orthosteric or allosteric ways.
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover functional protein degraders using a specific E3 ligase and a neosubstrate of interest.
Our platforms can use canonical small molecule HTS approaches or our proprietary DNA encoded peptide and macrocycle libraries.
OUR PIPELINE
Our internal programs are focused on oncology. We select targets based on oncogene addiction and synthetic lethality.
THE FOUNDING TEAM
Maria Soloveychik
Co-Founder & Chief Executive Officer
Charly Chahwan
Co-Founder & Chief Science Officer
ADVISORY BOARD
Arvind Gupta
Director
Andrew Perlman, MD, PhD
SAB
Leonard Post, PhD
SAB
OUR INVESTORS
OPEN POSITIONS
Imagine. Design. Build. Create.
Are you an enthusiastic scientist who wants to bring therapies into the clinic? Do you want to use synthetic biology to advance drug discovery? We are always keeping an eye out for new talented members to join the team.
RESEARCH ASSISTANT WITH MOLECULAR BIOLOGY EXPERTISE (BSC, OR MSC)
RESEARCH ASSISTANT WITH BIOCHEMISTRY EXPERTISE (BSC, OR MSC)
EXPERIENCED PROTEOMIC SCIENTIST (PHD+)
EXPERIENCED IMMUNOLOGIST (PHD+)
GET IN TOUCH
